Otsuka Holdings Co., Ltd. currently has the only therapy on the market for agitation associated with dementia due to Alzheimer’s disease, but its attempt to advance another therapy as a back-up has faltered.
Otsuka Counts The Cost Of Alzheimer’s Agitation Fail
The group will take a $770m impairment charge thanks to the Phase III failure of AVP-786 – but further trials continue.
